FindTrial
Sign In

EGFR tyrosine kinase inhibitor

DRUG2 trials

Sponsors

Zhejiang University, Taichung Veterans General Hospital

Conditions

CardiotoxicityDrug-Related Side Effects and Adverse Reactions (MeSH Term)Egfr Tyrosine Kinase InhibitorNon Small Cell Lung CancerNon-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)

Phase 2

Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression
NCT01998061
Zhejiang UniversityNon Small Cell Lung Cancer
Start: 2013-12-31End: 2015-12-31Target: 20Updated: 2013-12-20

Unknown Phase

Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer
CompletedNCT07267247
Taichung Veterans General HospitalCardiotoxicity, Drug-Related Side Effects and Adverse Reactions (MeSH Term), Egfr Tyrosine Kinase Inhibitor +1
Start: 2022-06-01End: 2024-04-30Updated: 2025-12-05

Related Papers

Continuation of epidermal growth factor tyrokine kinase inhibitor with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients.
Journal of Clinical Oncology2016-05-20